Kite raises $35m for NCI-backed cancer vaccine
This article was originally published in Scrip
Executive Summary
Kite Pharma has closed a $20 million series A financing and converted a further $15 million in previous promissory notes into stock to fund development of its cancer immunotherapies platform.